CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

BUY $RXRX

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

August 08, 2024 | Last Trade: US$6.91 0.15 2.22

SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporate Updates", the company's conference call should have been mentioned as having already taken place earlier this morning, rather than coming up later this afternoon as previously stated. The corrected bullet should have read:

L(earnings) Call: We will host a L(earnings) Call on Aug 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time. We will broadcast the live stream from Recursion’s X (formerly Twitter), LinkedIn, and YouTube accounts and there will be opportunities to ask questions of the company.

The rest of the release remains unchanged.

Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.

BUY $RXRX

Stock Quote

Last Trade:	US$6.91
Daily Change:	0.15 2.22
Daily Volume:	5,943,358
Market Cap:	US$1.900B

September 03, 2024 Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability August 08, 2024 Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities August 08, 2024 Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results June 26, 2024 Recursion Announces Proposed Offering of Class A Common Stock June 24, 2024 Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day LOAD MORE NEWS

BUY $RXRX

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE